ERBB2 and colorectal carcinoma: Other strategies being explored are anti-HER2 monoclonal antibody–drug conjugates, such as trastuzumab-emtansine (HERACLES-B and RESCUE assays), and trastuzumab-deruxtecan, at a 25% response rate documented in a phase I study in 12 patients with HER2-positive CRC [37].